

ZIM LABORATORIES LIMITED

Zeal & Innovation in Medicine

EARNINGS PRESENTATION Q1 FY27



People



Innovation



Quality



SAFE HARBOUR

The presentation has been prepared by **ZIM Laboratories Limited ("ZIM" or the "Company")** solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. By accessing this presentation, you are agreeing to be bound by the trading restrictions. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its affiliates, advisors or representatives are under an obligation to update, revise or affirm.

Certain statements contained in this presentation may be statements of the Company's beliefs, plans and expectations about the future and other forward-looking statements. The forward-looking statements are based on management's current expectations or beliefs as well as a number of assumptions about the Company's operations and facts beyond the Company's control or third-party sources and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward looking statements, which speak only as of the date of this presentation.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. You acknowledge and agree that the Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.

Table of Content

01

Q1 FY27 Highlights

Financial performance snapshot for the quarter

02

Financial Performance Q1 FY27

Revenue, EBITDA, margins and R&D investment trends

03

Business Mix

Product and market mix driving the revenue profile

04

R&D & Innovation

NIP & OTF pipeline progress, approvals and investment

05

Shareholding

Ownership structure and trading volumes - BSE + NSE

Q1 FY27 FINANCIAL HIGHLIGHTS

Q1 FY27 Vs Q1 FY26



Total Operating Income

₹942 Mn

₹718 Mn



▲ 31.2%



EBITDA

₹34 Mn

₹57 Mn



▼ 40.0%




EBITDA Margin

3.7%

7.9%



▼ 430 bps



Total R&D Spend*



₹82 Mn



8.7% of TOI

*Incl. ₹34 Mn towards BE studies & regulatory filings

Filings & Approvals



17
Total Filings

10
MAs Received

3
Filing Types

NIP · ODS · FF Generic for the Developed, Pharmerging & RoW Markets

STATUS UPDATE & PROGRESS ON EU-GMP CAPA REMEDIATION

Most of the CAPA remediation plan has been **completed and implemented**

- 01** **Q2 FY26**
June / July EU GMP Inspection. Onboarding External Consultant for CAPA Plan. Submission of comprehensive CAPA Remediation Plan. Capital Expenditure Orders placed for key systems needed. Contract Manufacturing for alternate site with accreditations finalised for Star Product 1.
- 02** **Q3 FY26**
Submission of CAPA Progress for upto October 2026. Appointment of European Consultant for CAPA Remediation. Strengthening Team in QMS. Training of Team. Additional CMO for specific markets being finalized. Hiring of QA Head.
- 03** **Q4 FY26**
Independent assessment by European + Indian Consultant. Effectiveness check on CAPA remediation progress . Validation by Consultants . Submission of CAPA Progress.. Initiatives on triggering Audits from other regions. Filing Batches from CMO Partners for Star Product 1. Pre-Audit by External Consultants.. Potential Re-Audit of facility by EMA inspectors.
- 04** **Q1 FY27**
Registration of Products in Pharmerging & RoW Markets. Feedback on other Audits : Re-Audit of facility by EMA inspectors. Launch of Star Product 1 in Alternate Markets. Extend alternate manufacturing strategy to other markets.
- 05** **Q2 FY27**
CAPA Submission planned after receipt of final report from EMA inspectors. Secure order for Star Product 1 in other developed markets. Start planning for supplies to EU and UK markets by planning for Raw Material availability and production readiness

Q2 FY26 Complete

Q3 FY26 Complete

Q4 FY26 Complete

Q1 FY27 Complete


Q2 FY27 In Progress



In addition to this, we underwent TGA Audit and PIC/S Malaysia audit


TOTAL OPERATING INCOME

Total Operating Income (₹Mn)



- Total Operating Income at ₹942 Mn, up 31.2% YoY
- Total Operating Income down 10.5% QoQ due to war situation in the Mid East and serious logistic challenges; some early signs of improvement


EBITDA & EBITDA Margin




- EBITDA at ₹34 Mn, down 40% YoY; EBITDA margins at 3.7% vs 7.9% in Q1 FY26.
- Gross contribution margins remained in line with margins for the year FY26 and the previous quarter
- Lower EBITDA margins primarily due to increased utility and employee costs

EXPENSE BRIDGE: Q1 FY26 → Q1 FY27

Employee benefits & other operating expenses · ₹ Mn




PAT & PAT Margin



- PAT at ₹ (40 Mn) in Q1 FY27 declined from ₹(19) Mn in Q1 FY26 ; mainly due to flow through of lower EBITDA.
- Increase in depreciation and finance costs are a direct outcome of investments now in place to support the next phase of scale-up.

PHARMACEUTICAL & NUTRACEUTICAL : MIX %


Pharma vs Nutra - Quarterly Revenue (₹ Mn) & Pharma Mix (%)



- Pharma business contributed 72% (₹ 673 Mn) of total revenue, while Nutra contributed 28% (₹ 268 Mn).
- Pharma business contribution increased 20 % while Nutra business contribution increased 71% YoY


INNOVATIVE PRODUCT CONTRIBUTION

(NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%)



- Innovative Product revenue (NIP + OTF) increased 3x YoY to Rs 138 Mn in Q1FY27; contribution increased to 15% from 6% in Q1FY26
- Innovative Product contribution including dossier licensing fees increased to 18% of Total Operating Income
- We continue to build on our robust innovative product development pipeline and have momentum in registrations.

Business Mix (₹ Mn) & Export (%)



- Export business share is at 84% of revenue in Q1 FY27
- Export Business increased 31.7% YoY while domestic business grew 24% YoY

ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK)


12 products in active development across **7 therapy areas** - **3 regulatory approvals secured** · Several products ready for filing

Product	Therapy Area	Market Review	Formulation Dev.	Validation	BE Studies	Reg. Filing	Reg. Approval	Commercial Supplies
Product 1	Urology							
Product 2	Gastrointestinal							
Dabigatran Etexilate	Anti-Coagulant						✓	
Di-Methyl Fumarate	CNS						✓	
Product 5	Urology							
Product 6	Rheumatoid Arthritis							
Azithromycin Susp.	Anti-Infective						✓	
Product 8	Analgesic							
Product 9	Gastrointestinal							
Product 10	Gastrointestinal							
Product 11	Skin Disorders (Anti-psoriatic)							
Product 12	Urology							

Some of these products have been commercialised in RoW markets including India (B2B)

ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK)

5 OTF products across 3 therapy areas - 3 regulatory approvals secured



Some of these products have been commercialised in RoW markets including India (B2B)



Q1 FY27 : ₹34 Mn

allocated for BE studies & registrations, advancing the Innovative Products (NIP + OTF) pipeline

109

R&D Team Size*

91

Post-Graduates

2

PhDs

8


NIP Filed in EU to date

4

Versatile Technology Platforms

* Includes 27 people from Regulatory Affairs;
Net R&D Team is 82 with 71 Postgraduates and 2 PhDs

R&D EXPENSE MIX & INVESTMENT AS % OF OPERATING INCOME




Q1 FY27 : Total R&D allocation of ₹82 Mn focused on product development, dossier upgrades, registrations & infrastructure


INCOME STATEMENT

Particulars (₹ Mn)	Q1FY27	Q1FY26	YoY%	Q4FY26	QoQ%
Total Operating Income	942	718	31.2%	1,053	-10.5%
Other Income	10	15	-32.8%	62	-84.0%
Total Income	952	733	30.0%	1,115	-14.6%
EBITDA	34	57	-40.0%	134	-74.2%
EBITDA %	3.7%	7.9%	(430) Bps	12.7%	(900) Bps
Finance Cost	36	33	10.3%	33	10.4%
Depreciation	54	48	10.4%	52	3.3%
Profit/(Loss) Before Tax (PBT)	(56)	(24)	129.0%	49	-214.8%
PBT %	(5.9%)	(3.3%)	(250) Bps	4.6%	(1050) Bps
Profit/(Loss) After Tax (PAT)	(40)	(19)	114.2%	37	-207.4%
PAT %	(4.3%)	(2.6%)	(170) Bps	3.6%	(780) Bps
EPS (₹ / Share)*(not annualised)	(0.75)	(0.38)	97.4%	0.76	-198.7%

Ownership % (June 2026)



Traded Volume (In K) - BSE + NSE



Shareholders : 14.5 K

Promoter Holding : Free of any encumbrance



Zeal & Innovation in Medicine

Zeal & Innovation in Medicine · ZIM Laboratories Limited · Nagpur, Maharashtra

Mr. Zain Daud

ZIM Laboratories Limited

zain.daud@zimlab.in

+91 9022 434631

Address : Sadoday Gyan (Ground Floor),
Opposite NADT, Nelson Square,
Nagpur, Maharashtra 440013

www.zimlab.in

+91 712 2981960

INVESTOR RELATIONS & CONTACT

Ms. Deepika Sharma
Go India Advisors

deepika@goindiaadvisors.com
+91 8451 02951

Ms. Priya Sen
Go India Advisors

priya@goindiaadvisors.com
+91 8334 841047

Ms. Sheetal Khanduja
Go India Advisors

sheetal@GoIndiaAdvisors.com
+91 97693 64166